Are we facing a cure in lung cancer?-KEYNOTE-001 insights

被引：6

作者：

Cohen, Aharon Y.

Kian, Waleed

Roisman, Laila C.

Levitas, Dina

Peled, Nir ^{[1
,2
,3
]}

Dudnik, Yulia

机构：

[1] Legacy Heritage Oncol Ctr, Oncol Div, POB 653, Beer Sheva, Israel

[2] Soroka Med Ctr, Dr Larry Norton Inst, POB 653, Beer Sheva, Israel

[3] Ben Gurion Univ Negev, POB 653, Beer Sheva, Israel

来源：

ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷

关键词：

CLINICAL ACTIVITY; OPEN-LABEL; PHASE IB; CANCER; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY; RADIOTHERAPY;

D O I：

10.21037/atm.2019.08.87

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3

共 15 条

[1] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].

Ahn, M. -J. ;

Yang, J. ;

Yu, H. ;

Saka, H. ;

Ramalingam, S. ;

Goto, K. ;

Kim, S. -W. ;

Yang, L. ;

Walding, A. ;

Oxnard, G. R. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115

[2] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[3] Pembrolizumab plus Chemotherapy in Lung Cancer [J].

Gil-Sierra, Manuel D. ;

Fenix-Caballero, Silvia ;

Alegre-del Rey, Emilio J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11)

[4] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC [J].

Lisberg, A. ;

Cummings, A. ;

Goldman, J. W. ;

Bornazyan, K. ;

Reese, N. ;

Wang, T. ;

Coluzzi, P. ;

Ledezma, B. ;

Mendenhall, M. ;

Hunt, J. ;

Wolf, B. ;

Jones, B. ;

Madrigal, J. ;

Horton, J. ;

Spiegel, M. ;

Carroll, J. ;

Gukasyan, J. ;

Williams, T. ;

Sauer, L. ;

Wells, C. ;

Hardy, A. ;

Linares, P. ;

Lim, C. ;

Ma, L. ;

Adame, C. ;

Garon, Edward B. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1138-1145

[5] Abscopal effect of radiotherapy combined with immune checkpoint inhibitors [J].

Liu, Yang ;

Dong, Yinping ;

Kong, Li ;

Shi, Fang ;

Zhu, Hui ;

Yu, Jinming .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11

[6] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

[7] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

[8] Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial [J].

Reck, Martin ;

Schenker, Michael ;

Lee, Ki Hyeong ;

Provencio, Mariano ;

Nishio, Makoto ;

Lesniewski-Kmak, Krzysztof ;

Sangha, Randeep ;

Ahmed, Samreen ;

Raimbourg, Judith ;

Feeney, Kynan ;

Corre, Romain ;

Franke, Fabio Andre ;

Richardet, Eduardo ;

Penrod, John R. ;

Yuan, Yong ;

Nathan, Faith E. ;

Bhagavatheeswaran, Prabhu ;

DeRosa, Michael ;

Taylor, Fiona ;

Lawrance, Rachael ;

Brahmer, Julie .

EUROPEAN JOURNAL OF CANCER, 2019, 116 :137-147

[9] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[10] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].

Rittmeyer, Achim ;

Barlesi, Fabrice ;

Waterkamp, Daniel ;

Park, Keunchil ;

Ciardiello, Fortunato ;

von Pawel, Joachim ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Kowalski, Dariusz M. ;

Dols, Manuel Cobo ;

Cortinovis, Diego L. ;

Leach, Joseph ;

Polikoff, Jonathan ;

Barrios, Carlos ;

Kabbinavar, Fairooz ;

Frontera, Osvaldo Aren ;

De Marinis, Filippo ;

Turna, Hande ;

Lee, Jong-Seok ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

He, Pei ;

Chen, Daniel S. ;

Sandler, Alan ;

Gandara, David R. .

LANCET, 2017, 389 (10066) :255-265

← 1 2 →